Investigational Drug Details
| Drug ID: | D199 |
| Drug Name: | L-alanine |
| Synonyms: | (2S)-2-aminopropanoic acid; (S)-2-aminopropanoic acid; (S)-alanine; Alanine; L-2-Aminopropionic acid; L-alanine; L-alpha-Alanine; L-α-alanine |
| Type: | Chemical drug |
| DrugBank ID: | DB00160 |
| DrugBank Description: | Alanine is a non-essential amino acid that occurs in high levels in its free state in plasma. It is produced from pyruvate by transamination. It is involved in sugar and acid metabolism, increases immunity, and provides energy for muscle tissue, brain, and the central nervous system. |
| PubChem ID: | 5950 |
| CasNo: | 56-41-7 |
| Repositioning for NAFLD: | Yes |
| SMILES: | [C@@H](C(=O)O)(C)N |
| Structure: |
|
| InChiKey: | QNAYBMKLOCPYGJ-REOHCLBHSA-N |
| Molecular Weight: | 89.094 |
| DrugBank Targets: | Serine--pyruvate aminotransferase; 4-aminobutyrate aminotransferase, mitochondrial inhibitor; Kynureninase; Alanine--tRNA ligase, mitochondrial; 5-phosphohydroxy-L-lysine phospho-lyase; Alanine aminotransferase 2; Alanine aminotransferase 1; Cysteine desu |
| DrugBank MoA: | L-Alanine is a non-essential amino acid that occurs in high levels in its free state in plasma. It is produced from pyruvate by transamination. It is involved in sugar and acid metabolism, increases immunity, and provides energy for muscle tissue, brain, and the central nervous system. BCAAs are used as a source of energy for muscle cells. During prolonged exercise, BCAAs are released from skeletal muscles and their carbon backbones are used as fuel, while their nitrogen portion is used to form another amino acid, Alanine. Alanine is then converted to Glucose by the liver. This form of energy production is called the Alanine-Glucose cycle, and it plays a major role in maintaining the body's blood sugar balance. |
| DrugBank Pharmacology: | Is an important source of energy for muscle tissue, the brain and central nervous system; strengthens the immune system by producing antibodies; helps in the metabolism of sugars and organic acids. |
| DrugBank Indication: | Used for protein synthesis. |
| Targets: | KYNU |
| Therapeutic Category: | -- |
| Clinical Trial Progress: | Clinical trial completed (NCT00586885: No therapeutic effect of L-alanine in patients with nonalcoholic steatohepatitis.) |
| Latest Progress: | Failed in clinical trials |
| Trial ID | Source ID | Phases | Status | Study Results | Start Date | Last Update Posted | |
|---|---|---|---|---|---|---|---|
| L0217 | NCT00586885 | Not applicable | Completed | No Results Available | February 2004 | October 11, 2012 | Details |
| Target ID | Target Name | GENE | Action | Class | UniProtKB ID | Entry Name |
|---|
| Article ID | PMID | Source | Title | |
|---|---|---|---|---|
| A05742 | 33135718 | Food Funct | Integrative transcriptomics and metabolomics explore the mechanism of kaempferol on improving nonalcoholic steatohepatitis. | Details |
| A20461 | 25947379 | J Biol Chem | 1-Deoxysphingolipids Encountered Exogenously and Made de Novo: Dangerous Mysteries inside an Enigma. | Details |
| A36981 | 16781459 | Free Radic Biol Med | Hydrogen sulfide inhibits nitric oxide production and nuclear factor-kappaB via heme oxygenase-1 expression in RAW264.7 macrophages stimulated with lipopolysaccharide. | Details |